THERAPY DOSSIER · th-ec807ab07cfc

Adeno-associated virus vector expressing the astrocyte-specific Gfa2 promoter and the NFAT-inhibitory peptide VIVIT (AAV-Gfa2-VIVIT)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26843634 ↗2016Reported benefit

Blockade of Astrocytic Calcineurin/NFAT Signaling Helps to Normalize Hippocampal Synaptic Function and Plasticity in a Rat Model of Traumatic Brain Injury.

RatTBIControlled cortical impactSprague-DawleyMale

Model: Controlled cortical impact traumatic brain injury

AAV-Gfa2-VIVIT prevented the injury-related loss of basal CA1 synaptic strength and key synaptic proteins, reduced susceptibility to long-term depression and increased SPARCL1 expression, without altering GFAP or Iba1 levels.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…